Business & Investment

Funded biopharmacy company stock

The company is at the forefront of the global fight against infectious diseases with the goal of developing new treatments to prevent death and improve lives.

Appili Therapeutics (TSX: APLI) is an infectious disease biopharmacy company whose mission is to resolve life-threatening infectious diseases. The company is part of a consortium sponsoring late-stage clinical trials evaluating the antiviral drug Avigan / Reeqonus for the global treatment and prevention of COVID-19.

Financing revenue evaluates oral antivirals for the treatment of mild to moderate COVID-19, provides this highly needed drug, and hopefully changes the course of this pandemic, the company’s number one Useful for 3-phase PRESECO trials.

In the afternoon trading, stock prices rose nearly 3%.

Funded biopharmacy company stock Funded biopharmacy company stock

Back to top button